Agree..
and the other issue is the demographics...
Cost aside (and OSL will be cheaper than Sirtex spheres), it is easier to inject percutaneously than intra-arterially and that may be important when treating larger numbers of patients in areas where the technical expertise is less than in the USA, Europe and Australia
http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics
Liver cancer is much more common in countries in sub-Saharan Africa and Southeast Asia than in the US. In many of these countries it is the most common type of cancer
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.015(1.30%) |
Mkt cap ! $21.46M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.16 | $1.14 | $25.56K | 22.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14709 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 14688 | 2 |
View Market Depth
| Last trade - 11.40am 28/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |